VANCOUVER, BC, August 10, 2021 – Syniad Innovations Inc (“Syniad”) is pleased to announce that the shares of Gemina Laboratories Ltd (“Gemina”) have been admitted to trading on the Canadian Securities Exchange under the symbol GLAB.
Syniad co-founded Gemina in 2020, to create a world-leading biosensing company. Gemina’s objective is to deliver diagnostic testing at the point of need. Its technology platform has the potential to address a wide range of pathogens, for example, the rapid testing of COVID-19, Influenza and a variety of other viruses and conditions.
Today’s news marks the first public market event from the Syniad portfolio of ventures.
John Davies, Syniad’s CEO, commented, “Today’s milestone illustrates how the Syniad team can source fantastic early-stage science, build an exciting venture, and take that venture public within a 16-month timeframe. Gemina is currently on a positive trajectory, and I’d like to express my thanks to the Gemina team and all Gemina’s stakeholders who have worked very hard to create this success.”